Australia (Commonwealth)

Australia Therapeutic Goods (Medical Devices) Regulations 2002

75 controls. 0 other frameworks in our corpus share controls with it. Here is all of it, and how much of it you are already doing.

Page built . This page is derived from the framework corpus, which changes when the corpus is extended rather than daily.

75 controls 0 frameworks share controls with it Australia (Commonwealth) verified against its source document

Every control below is one this framework asks for. The right hand column counts how many other frameworks in our corpus carry the same control, which is the difference between doing this work once and doing it again for the next standard.

There is no implementation kit for this framework yet. The control list and the overlap above are free and complete.

What you already have

Frameworks whose controls overlap this one, most first. If you run any of them, the count is roughly what you have already evidenced.

No measured overlap with another framework in the corpus.

Every control

CodeControlAlso in
fees-transitionalWaivers, fees, transitional and application provisions, Schedule 5 and the endnotes: charges and fees, the 2010 to 2026 amendment transitions and the currency of this compilation0
r1.1-1.8Preliminary: name, dictionary, devices with a measuring function, refurbishment, common characteristics of a kind of device, nomenclature codes and health professionals who are not0
r10.1-10.7Miscellaneous machinery: authorised persons, implantable breast and cardiac device registries, delegations, software forms and reconsideration and tribunal review of decisions0
r10.2Sponsor identification: provide the sponsor's name and address with the device so users can readily identify the sponsor, located as clause 13.2 requires, and never let an added la0
r10.3-10.3ACustom-made devices: notify the Secretary within 2 months of first manufacture in Australia or first import, and give an annual report on the approved form before 1 October coverin0
r2.1-3.1Essential principles and the classification scale: Schedule 1 sets the essential principles for section 41CA of the Act; devices are ranked I, IIa, IIb and III, and IVDs 1 to 40
r3.11-sch3-8Apply the clinical evaluation procedures to every device (custom-made devices included): obtain clinical investigation data or a documented literature review, evaluate it through c0
r3.12Provide all records and correspondence on the application of the conformity assessment procedures in English0
r3.2-3.3Classify every device by its intended purpose under Schedule 2 (non-IVD) or Schedule 2A (IVD), applying the regulation 3.3 principles for combinations, accessories, software, produ0
r3.4-3.10Apply the conformity assessment procedures the Regulations set for the device's class (or a higher class's procedures if preferred), including the extra steps for sterile, measurin0
r4.2-4.4Conformity assessment certificates: what the Secretary considers, decision time, priority applicant determinations, certificate content and suspension revocation timing0
r4.6-4.11Keep the certificate holder accurate: notify the Secretary within 3 months of the manufacturer's death, bankruptcy, winding up or change of name, apply within 3 months to change th0
r4A.1-4A.9Australian conformity assessment bodies: purpose, applications, assessment and duration of conformity assessment body determinations0
r4A.10-4A.16Australian conformity assessment bodies: comply with Schedule 3AA, tell the Secretary of substantial changes within 10 working days and of planned cessation, allow entry and inspec0
r4A.17-4A.18Australian conformity assessment bodies: certify only where an appropriate procedure has been applied, vary, suspend or revoke certificates when no longer satisfied, notify the Sec0
r5.10Automatic condition: record complaint and adverse event information and each distribution of the device as soon as practicable and keep the records 10 years for Class III, implanta0
r5.11Automatic condition: for Class III, implantable Class IIb and Class 4 IVD devices, give the Secretary an annual report before 1 October for the first three reporting periods after 0
r5.12Automatic condition: for higher-risk IVDs, self-test and point-of-care IVDs and spinal fusion implants, notify the Secretary at least 20 business days before importing, supplying o0
r5.13Automatic condition: do not supply in Australia a device containing a scheduled poison where that supply would breach Part 2 of the current Poisons Standard0
r5.2-5.4D-6.1Inclusion in the Register: period to obtain manufacturer information, applications selected for mandatory audit, priority applicant determinations and suspension revocation timing0
r5.7Automatic condition: report adverse events to the Secretary within 48 hours for a serious public health threat, 10 days for a death or serious deterioration, 30 days where recurren0
r5.8-5.8AAutomatic condition: hold and give, when required, information on any malfunction, deterioration, design, labelling, instruction or advertising inadequacy or use that led to any co0
r5.9Automatic condition: store and transport devices under the sponsor's control in line with the manufacturer's instructions for use and accompanying information0
r7.2Category A patients: use an unapproved device only with informed consent and at the treating medical practitioner's direction, complete the approved Category A statement, and send 0
r7.3-sch4-2.3Clinical trials: notify the Secretary (CTN) before the device is used and before each new site starts, approve the trial on ethics committee advice no less restrictively, give Nati0
r7.6-7.8Authorised prescribers: supply under an authority only as its directions allow, and when a health practitioner supplies a device under the authorised prescriber scheme notify the p0
r8.1A-8.1Answer information notices under section 41JA within the set period and keep manufacturing records for 5 years and distribution records for 10 years (Class III and implantable Clas0
r8AAHealthcare facilities (hospitals and day hospitals): report to the TGA electronically adverse events involving Class III and Class 4 IVD devices within 10 days of a death or seriou0
r9A.1Australian Unique Device Identification Database: the Secretary establishes and maintains the database, limits personal information, retains entries during suspension or cancellati0
sch1-1Essential principle 1: design and produce the device so that, used as intended by suitably trained users, it does not compromise the patient's condition or anyone's safety, and its0
sch1-10Essential principle 10: a device with a measuring function must measure accurately, precisely and stably within stated limits, use ergonomic scales and express results in Australia0
sch1-11Essential principle 11: minimise patient, user and bystander exposure to intended and stray radiation, give users control and warnings for hazardous emissions, document radiation i0
sch1-12.1-aEssential principle 12.1(1) to (4): programmed devices and software as a medical device must be safe, reliable, accurate, usable, secure and repeatable for their purpose, fail safe0
sch1-12.1-bEssential principle 12.1(5) and (6): build and maintain cybersecurity by best practice (protection against unauthorised access, vulnerability management, patching, disclosure and u0
sch1-12.12-12.13Essential principles 12.12 and 12.13: devices that deliver energy or substances must set and hold the delivered rate and amount accurately, prevent accidental dangerous release, fl0
sch1-12.2-12.4Essential principles 12.2 to 12.4: where patient safety depends on power, provide a means to check an internal supply and an alarm for external power failure, and fit clinical-para0
sch1-12.5-12.11Essential principles 12.5 to 12.11: minimise electromagnetic interference with nearby equipment and protect people against electric shock, mechanical, vibration, noise, connector a0
sch1-13.1-13.3Essential principles 13.1 to 13.3: provide in English, legibly and in the right place (device, packaging or leaflet), the information that identifies the device and manufacturer an0
sch1-13.4Essential principle 13.4: supply instructions for use carrying every applicable clause 13.4 table item, unless a Class I, IIa or Class 1 IVD device can be used safely without them0
sch1-13.5-13.6UDI on the device: from the device's general start day provide the UDI device identifier and production identifier in human- and machine-readable form on the device, else its packa0
sch1-13AEssential principle 13A: for implantable and active implantable devices in scope, make a patient implant card (or electronic equivalent) and a patient information leaflet (or elect0
sch1-13BEssential principle 13B: make the current software version number and build number accessible and identifiable to users, in English0
sch1-13C.1UDI identifiers: obtain the UDI device identifier and packaging identifiers from a single UDI issuing agency and allocate production identifiers under that agency's rules0
sch1-13C.2-13C.4AusUDID entries: include each model's device identifier, issuing agency, packaging identifiers and the clause 13C.3 data elements within 30 days of first supply on or after the gen0
sch1-13C.5UDI direct marking: from the direct marking start day, directly mark reusable devices that are reprocessed between patients with the device and production identifiers, in both form0
sch1-14Essential principle 14: hold clinical evidence suited to the device's use and class that demonstrates compliance with the applicable essential principles0
sch1-15Essential principle 15: IVD devices must have analytical and clinical performance that supports the intended use, address accuracy, precision, sensitivity, specificity, stability, 0
sch1-2Essential principle 2: choose design and construction solutions that follow safety principles and the state of the art, in the order identify hazards, design them out, protect agai0
sch1-3Essential principle 3: the device must perform as the manufacturer intends and be designed, produced and packaged to suit a therapeutic purpose within the definition of a medical d0
sch1-4Essential principle 4: within its stated safe-use life, under normal stresses and with maintenance and calibration done as instructed, the device must keep the safety and performan0
sch1-5Essential principle 5: design, produce and pack the device so that transport and storage done in line with the manufacturer's instructions do not degrade its characteristics or per0
sch1-6Essential principle 6: the benefits of using the device for its intended performance must outweigh any undesirable effects0
sch1-7.1-7.3Essential principles 7.1 to 7.3: select materials for their chemical and physical properties and biocompatibility, minimise contaminants and residues, and make the device safe with0
sch1-7.4Essential principle 7.4: where a device incorporates a substance that would be a medicine if used alone and acts ancillary to the device, verify the substance's safety and quality 0
sch1-7.5-7.7Essential principles 7.5 to 7.7: minimise risks from substances leaching out, from unintended ingress or egress of substances, and from released particles, with particular attentio0
sch1-8.1-8.2Essential principles 8.1 and 8.2: eliminate or minimise infection risk, make the device easy to handle without cross-contamination, and control non-viable animal, microbial or reco0
sch1-8.3-8.5Essential principles 8.3 to 8.5: supply sterile devices sterile by a validated method in controlled conditions with packaging that keeps them sterile, pack non-sterile devices to k0
sch1-9Essential principle 9: make the device safe in combination with other devices and equipment and remove or minimise physical, environmental, interference, maintenance, ageing, accur0
sch3-1.3-1.4Full quality assurance: implement a quality management system covering design, production, packaging, labelling and final inspection, have it assessed, document it fully and build 0
sch3-1.5-1.6Full quality assurance: notify and have assessed any substantial change to the system or to the devices it covers, and for Class III, Class 4 IVD and Class 4 in-house IVD devices a0
sch3-1.7-1.9Full quality assurance: on request give the Secretary system documentation, design and manufacturing data and arrange tests; make a signed declaration of conformity with the clause0
sch3-2Type examination: arrange examination of a representative sample with complete design, manufacturing, standards, test, clinical and labelling documentation, supply samples on reque0
sch3-3Verification: have each device or a statistical batch sample examined and tested against the approved type or the technical documentation, keep production uniform, operate post-mar0
sch3-4Production quality assurance: implement and have assessed a quality management system for production and final inspection that ensures devices match the approved type or technical 0
sch3-5Product quality assurance: implement and have assessed a product quality management system for final inspection and testing of each device or batch sample against the approved type0
sch3-6.3-6.4Declaration of conformity route: prepare and keep current technical documentation that would let the Secretary assess compliance, covering description, design drawings, sterilisati0
sch3-6.5Declaration of conformity route: establish and keep up to date a post-marketing system that reviews post-production experience, applies corrective action and promptly notifies the 0
sch3-6.6-6.7Declaration of conformity route: make a signed clause 6.6 declaration stating device identifiers, class, nomenclature code, any additional procedures and certificate numbers, and k0
sch3-6AClass 1 to 3 in-house IVDs: notify the Secretary of every in-house IVD manufactured, maintain NATA (or approved body) accreditation to ISO 15189 or ISO/IEC 17025 and meet the NPAAC0
sch3-6BClass 4 in-house IVDs: implement a quality management system for design to final inspection, meet the blood and tissue GMP code and licence or NATA ISO 15189 accreditation with the0
sch3-7.2Custom-made devices: prepare and supply with each device a signed statement identifying the device, patient, requesting health professional and design characteristics and confirmin0
sch3-7.5System or procedure packs: make a signed clause 7.5 declaration confirming conformity evidence for each device, registered medicines, compatible contents used within intended purpo0
sch3AUnused emergency medical devices: when an emergency exemption ends, notify the devices on hand, store and dispose of them as the Secretary directs (destruction, export, supply or r0
sch4-2.12-2.13Custom-made device exemption conditions: the manufacturer (or, for imports, the sponsor's procedures) must keep conformity or design and manufacturing information available, allow 0
sch4-2.14-2.20Conditional exemptions for patient-matched devices, clinical decision support software, Class 1 to 4 in-house IVDs for specified purposes, surgical loan kits, therapeutic vaping de0

Tell me when Australia Therapeutic Goods (Medical Devices) Regulations 2002 files something new

One email when a public company newly discloses something this framework governs, naming the company and what our corpus says it puts in scope. Nothing else, and one click to stop.

What this page is

A control-level reference for Australia Therapeutic Goods (Medical Devices) Regulations 2002, drawn from our framework corpus. Control codes and titles are references to the standard, not reproductions of it. The overlap counts and the auditor artefacts are our own work and are the part you will not find elsewhere.

Measure this against what you already run · All frameworks · Today's edition